

Name of the Company



HERANBA
INDUSTRIES LIMITED
A Govt. Recognised* Export House

KEY IPO Highlights

Subscription Period:

23rd Feb., 2021 to 25th Feb., 2021

Issue Size: 9.98 Mn shares
(aggregating up to INR 625.24 Cr)

Price Band: INR 626 to 627

Lot Size: 23 Shares

Listing Date:

5th March, 2021

About the Company

- Gujarat based crop protection chemical manufacturer.
- One of the leading domestic producers of synthetic pyrethroids like cypermethrin, deltamethrin, lambda-cyhalothrin, etc.
- Company has 3 well-equipped manufacturing units in Vapi, Gujarat with an aggregate manufacturing capacity of 14,024 MTPA.
- In India, it has 8600 dealers across 16 states and 1 union territory whereas, in the overseas market, it exports its products to more than 60 countries through international distribution partners.

Objects of the Issue:

- To meet business working capital requirements.
- To meet general corporate purposes.
- To meet public issue expenses..

Financial Overview (INR Million)

Particulars	Sep-20	Mar-20	Mar-19	Mar-18
Total Assets	7,881	6,248	5,604	4,505
Total Revenue	6,192	9,679	10,118	7,504
Profit After Tax	663	978	754	469

P / E Multiples

Heranba P/E — 14.66

Sumitomo Chemicals P/E — 72.3

Punjab Chemicals P/E — 66.2

Sector P/E — 70.8

Recommendation from major brokerage houses

SUBSCRIBE

Neutral

CAPITAL MARKET



AJCONGLOBAL
YOUR FRIENDLY FINANCIAL ADVISORS

AXIS CAPITAL
It's possible

Prabhudas Lilladher
POWERING YOUR FINANCIAL GROWTH

ICICI direct.com

Emkay
Your success is our success

Sharekhan

Angel Broking

Highlights:

- Range of product portfolio including Intermediates, Formulations, and Technical.
- Domestic as well as global reach.
- Strong distribution network.
- Large customer base.
- Experienced promoters and management team.

Kreo Capital Opinion

- With current point of view company has a stable financial growth over the years & it has been generating positive cash flow. So we take a neutral to positive stance on this IPO & recommend subscribe on this IPO for long term perspective

Disclaimer: The recommendations stated above are given by individual advisors (including Kreo Capital). Investors are advised to consult their financial advisor and do their own due diligence before subscription.